Table 3. Stratified analysis of CYP17 polymorphism with prostate cancer risk.

Genetic model* (No.of studies) Overall(31)	Main effects of CYP17 polymorphism in cancer
	OR(95% CI)	P	Pheterogeneity	Analysis model↓
CC vs TT	1.03(0.86-1.24)	0.72	< 0.0001	R
CT vs TT	0.99(0.87-1.12)	0.88	0.0006	R
CC+CT vs TT	1.00(0.88-1.14)	0.97	< 0.0001	R
CC vs CT+TT	1.04(0.89-1.20)	0.65	0.001	R
Ethnic groups
African(6)
CC vs TT	1.51(0.95-2.40)	0.08	0.76	F
CT vs TT	1.27(0.66-2.42)	0.47	0.02	R
CC+CT vs TT	1.28(0.75-2.19)	0.37	0.06	R
CC vs CT+TT	1.56(1.01-2.39)	0.04	0.65	F
Asian(11)
CC vs TT	1.09(0.74-1.62)	0.66	0.001	R
CT vs TT	1.07(0.81-1.42)	0.63	0.005	R
CC+CT vs TT	1.07(0.79-1.45)	0.66	0.0003	R
CC vs CT+TT	1.02(0.80-1.31)	0.87	0.06	R
European(14)
CC vs TT	0.95(0.76-1.20)	0.68	0.002	R
CT vs TT	1.94(0.82-1.06)	0.31	0.07	R
CC+CT vs TT	0.98(0.82-1.07)	0.32	0.03	R
CC vs CT+TT	1.00(0.81-1.23)	0.97	0.001	R

*CC+CT vs TT: dominant model; CC vs CT+TT: recessive model. ^↓F: fixed-effects model; R: random-effects model.